Non-Small Cell Lung Cancer (NSCLC)

Vigil® EATC-NSCLC + nivolumab

The purpose of this open label, single arm Phase 2 study, is to understand the effects of VIGIL® in combination with nivolumab, when given to patients with metastatic non-small cell lung cancer (NSCLC) patients.  In this study, the sponsor and investigators are evaluating whether more patients treated with the combination of Vigil® and nivolumab respond or have a higher objective response rate (ORR) than the historical data of patients treated with single agent nivolumab in patients with advanced NSCLC.  

Patients interested in this study should contact the following center:

Texas

Dallas, Dr. Minal Barve, Mary Crowley Cancer Research Center, P: 972-566-3000 E: referral@marycrowley.org

Additional details of this trial may be found on clinicaltrials.gov NCT identifier: NCT02639234


 
Melanoma (skin cancer)

Pilot Study combining Vigil® - EATC-Mel and pembrolizumab

This open label study is seeking to evaluate the combination of Vigil® engineered autologous tumor cell (EATC-Mel) and pembrolizumab in patients with locally advanced or metastatic melanoma. The study will look for evidence of induced immunity by looking for a potential increase in CD8+ PD-1+ T cells and for PD-L1+ tumor cells, following three doses of single agent Vigil® and following three doses of Vigil® in combination with pembrolizumab.

Patients interested in this study should contact the following center:

  • Texas

Dallas, Dr. Minal Barve, Mary Crowley Cancer Research Center, P: 972-566-3000 E: referral@marycrowley.org 

Abilene, Dr. Anton M.S. Melnyk, Texas Oncology (center is not yet open)

Additional details of this trial may be found on clinicaltrials.gov NCT identifier:  NCT02574533


 
Triple Negative Breast Cancer (TNBC)

Pilot study combining Vigil®-EATC-TNBC and durvalumab

This open label pilot study is seeking to evaluate the combination of Vigil® Engineered Autologous Tumor Cells - Triple Negative Breast Cancer (EATC-TNBC) and MEDI4736 (durvalumab) in patients with locally advanced or metastatic triple negative breast cancer, regardless of the number of prior therapies.  The primary objective of the study is to determine how many patients (%) respond to the Vigil EATC-TNBC - durvalumab combination treatment (objective response rate by RECIST 1.1 and immune response criteria - irRC). The secondary objective is to determine how many patients (%) with PD-L1 negative TNBC, respond to the combination treatment (objective response rate (ORR) by RECIST 1.1).

Patients interested in this study should contact the following center:

Texas

Dallas, Dr. Minal Barve, Mary Crowley Cancer Research Center, P: 972-566-3000 E: referral@marycrowley.org

Additional details of this trial may be found on clinicaltrials.gov NCT identifier:  NCT02725489

    Cost to Patients

    Subjects will not be charged for participating in this clinical trial. Subjects will discuss any other costs associated with the clinical trial with their physician.